Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vor Biopharma

< Previous 1 2 Next >
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces $175 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Announces $55.6 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.